AzTrials
AzTrials

HydronephrosisFHYDONCT06896149

Mild Fetal Hydronephrosis, Gestational Diabetes and Spontaneous Resolution vs Moderate-severe Fetal Hydronephrosis, Obstructive Causes and Worse Postnatal Outcome

An observational study of Hydronephrosis and Gestational Diabetes, run by Fondazione Policlinico Universitario Agostino Gemelli IRCCS at 1 site in Italy.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Renal pelvis dilatation can be a relatively common finding on obstetric antenatal ultrasounds occurring in 1% to 5% of all pregnancies, with a known predilection for the male sex. Fetal hydronephrosis can be ascribed to structural obstructive conditions or functional origin causes. Read more about this study

Who is it for?
Ages Up to 55 years
Conditions the study is for
Hydronephrosis, Gestational Diabetes
What is being tested?
Obstetric ultrasound
Type of treatment
Pill or oral medicine
How many people
800 participants
Where
1 siteItaly
Study dates
1 Apr 2025to 28 Feb 2028
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Up to 55 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Study population: Pregnant women accessing the Obstetric ultrasound clinics and the obstetrics DH of Fondazione Policlinico A. Gemelli- IRCCS with or without a diagnosis of gestational diabetes, with ultrasound finding of fetal hydronephrosis of different grades and assessment of the evolution of hydronephrosis in the newborn in the first six months of postnatal life.

Who may be able to join

  • Written informed consent.
  • Single pregnancy in normal progression, in presence of single or bilateral fetal hydronephrosis of any grade of severity with or without a gestational diabetes diagnosis and without evidence of other ultrasound detectable abnormalities of the fetus affecting other anatomical districts (cases).
  • Single physiological pregnancy in normal evolution without finding of fetal hydronephrosis and gestational diabetes (controls).
  • Single pregnancy with a diagnosis of gestational diabetes in the absence of fetal hydronephrosis (controls).
  • Having performed at least one prenatal ultrasound at the obstetric ultrasound clinics and obstetric DH of the Foundation.
  • Have been screened for gestational diabetes.

Who cannot join

  • Detection of other major malformations and genetic syndromes in the fetus.
  • Twin pregnancies.
  • Maternal conditions such as diabetes insipidus, type I and type II diabetes mellitus.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Italy1 site
  • Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Ostetricia e patologia ostetrica

    Roma, Italia, 00168

    Anita Romiti, MD, +390630157028, anita.romiti@policlinicogemelli.it

    Anita Romiti

Other trials in Italy

About this study

Official title: Association Between Mild Fetal Hydronephrosis (G1-G2), Gestational Diabetes and Spontaneous Resolution in the First Year of Life vs Moderate-severe Fetal Hydronephrosis (G3-G4), Obstructive Causes and Worse Postnatal Outcome

Renal pelvis dilatation can be a relatively common finding on obstetric antenatal ultrasounds occurring in 1% to 5% of all pregnancies, with a known predilection for the male sex. Fetal hydronephrosis can be ascribed to structural obstructive conditions or functional origin causes. The latter are characterized by the transience of the clinical picture, which appears milder in degree, onset at later gestational ages, a course of substantial stability and spontaneous regression, sometimes as early as during pregnancy or early postnatal life. Fetal hydronephrosis related to structural obstructive causes, on the other hand, classically presents an earlier onset, a worsening course during pregnancy and often requires postnatal surgical correction. Additional ultrasound findings that contribute to prognosis include those indicative of an associated congenital anomaly of the kidneys and urinary tract (CAKUT). The risk of postnatal pathology in mild prenatal hydronephrosis is reported to be between 11% and 15%. It increases up to 27-45% in fetuses with moderate prenatal hydronephrosis and up to 53- 88% in cases of severe hydronephrosis. In the outpatient clinical practice of prenatal ultrasonography, is hypothesized an association between mild, mono- bilateral fetal hydronephrosis as an isolated ultrasound finding and gestational diabetes. In this population, this study aims to highlight the stability of the sonographic picture, relative improvement with effective glycemic control with diet or medical therapy, and subsequent spontaneous resolution in early postnatal life. A possible causal link between the two conditions could lie in the association of poorly controlled gestational diabetes with fetal hyperglycemia, which would cause increased osmotic diuresis resulting in polyuria and subsequent hydronephrosis. In contrast, is hypothesized an association between earlier-onset moderate-to-severe fetal hydronephrosis, its worsening progression throughout pregnancy and the anatomic abnormalities finding in the fetal urinary tract, in no correlation with maternal gestational diabetes. This condition correlates with increased postnatal complications (e.g., recurrent urinary infections, need for antibiotic prophylaxis, etc.) and a more severe postnatal outcome that may require surgical correction. To date, there is limited scientific literature concerning the functional causes of fetal hydronephrosis, as opposed to obstructive causes, which have been more analyzed and classified. This ambispective observational case-control study aims to evaluate pregnant women accessing the obstetric ultrasound and obstetric day hospital outpatient clinics of the Fondazione Policlinico A. Gemelli- IRCCS with ultrasound finding of mono-bilateral fetal hydronephrosis during the second and third trimester of pregnancy. In this population we will define the fetal hydronephrosis degree, its evolution, the association with maternal metabolic disorders, in order to estimate postnatal morbidity. All prenatal ultrasound images will be interpreted by the same group of specialists. To assess the degree of fetal hydronephrosis, the classification system developed by SFU in 1993 will be used. The latter is the most commonly used among pediatric urologists for grading neonatal and infant pelvic disorders:

  • grade 0: no dilatation, calico walls paired with each other
  • grade 1 (mild): dilation of the renal pelvis without dilation of the calyces
  • grade 2 (mild): dilatation of the renal pelvis (mild) and calyces
  • grade 3 (moderate): moderate dilatation of the renal pelvis and calyces; dulling of the fornixes and flattening of the papillae; possible mild cortical thinning
  • grade 4 (severe): gross dilatation of renal pelvis and calyces; cortical thinning.
Read more

The diagnosis of gestational diabetes will be defined by an altered oral glucose tolerance test (OGTT) result or elevated glycosylated hemoglobin (HBA1c) values. In addition, the presence of a flat OGTT trend suggestive of an insulin resistance condition will also be considered pathological. The OGTT will be performed between weeks 24 and 28 of pregnancy, as per the guidelines. In patients at high risk of developing gestational diabetes, early screening will be performed between sixteen and eighteen weeks of pregnancy. Amniotic fluid will be assessed according to one of the following ultrasound criteria:

  • calculation of amniotic fluid index (AFI) by summing the vertical depth of amniotic fluid measured in each quadrant of the uterus
  • With the single deepest pocket (SDP). Polydramnios is diagnosed when the amniotic fluid index (AFI) is ≥ 250 mm, the single deepest pocket (SDP) is ≥ 80 mm, or when the examiner subjectively assesses an increase in amniotic fluid. Oligohydramnios is diagnosed when the AFI is ≤ 50 mm or when the SDP is ≤ 20 mm.
Being tested
Obstetric ultrasound
Medical subject headings
Hydronephrosis, Diabetes, Gestational

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Obstetric ultrasoundDiagnostic test

    Also called Data collection of oral glucose tolerance test, fasting blood glucose, or glycated hemoglobin., Collection of postnatal kidney and urinary tract ultrasound examination data, performed according to clinical protocols, up to 6 months of postnatal life.

    Ultrasound focus on fetal renal pelvis, amniotic fluid assessment, and fetal weight estimation.

Study groups in NCT06896149
Study groupRoleWhat they receive
Fetal hydronephrosis (cases)* Single pregnancy in normal progression, in presence of single or bilateral fetal hydronephrosis of any grade of severity from G1 to G4 with a gestational diabetes diagnosis (cases). * Single pregnancy in normal progression, in presence of single or bilateral fetal hydronephrosis of any grade of severity from G1 to G4 without a gestational diabetes diagnosis (cases).
Receives: Diagnostic Test: Obstetric ultrasound
No fetal hydronephrosis (controls)* Single physiological pregnancy in normal evolution without finding of fetal hydronephrosis and gestational diabetes. * Single pregnancy with a diagnosis of gestational diabetes in the absence of fetal hydronephrosis.
Receives: Diagnostic Test: Obstetric ultrasound

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Mild fetal Hydronephrosis in patients with gestational diabetes

    This study aims to evaluate if gestational diabetes can be associated with mild grade (G1-G2) fetal hydronephrosis based on all clinical data present at the time of admission and obstetric ultrasound data.

    Measured: 1 year

Secondary outcomes (2)
  1. Fetal hydronephrosis grade in women with and without gestational diabetes

    to compare fetal hydronephrosis in pregnant women with and without gestational diabetes

    Measured: 3 years

  2. Moderate to severe fetal hydronephrosis and gestational diabetes

    To demonstrate the absence of association between moderate-to-severe fetal hydronephrosis (G3-G4) and gestational diabetes, collecting all clinical data present at the time of admission and obstetric ultrasound data.

    Measured: 3 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Mar 2025
  2. Study start1 Apr 2025 (estimated)
  3. Primary completion31 May 2026 (estimated)
  4. Study completion28 Feb 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
800 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06896149
Sponsor's protocol ID
7077
Acronym
FHYDO
Status last verified
Jan 2025
First submitted
29 Jan 2025
Last updated
26 Mar 2025
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Hydronephrosis and Gestational Diabetes, run by Fondazione Policlinico Universitario Agostino Gemelli IRCCS at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 26 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Anita Romiti (+390630155701, anita.romiti@policlinicogemelli.it), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Mild fetal Hydronephrosis in patients with gestational diabetes (time frame: 1 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Mar 2025.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in